depression

FDA approves first brain stimulation device for home depression treatment. Flow Neuroscience's FL-100 headset uses electrical stimulation for adults, available in 2026.

VANCOUVER, British Columbia, Jan. 19, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.comNews Commentary – Consumer healthcare markets hit a massive $362 billion entering 2026, but smart money is shifting toward regulatory certainty rather than just market size[1]. Modern health organizations are using...

(NaturalNews) A major Danish study found that depression in older adults can act as an early biological warning sign for Parkinson's disease and Lewy body demen...

WILMINGTON, Del., Jan. 16, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) (the "Company"), a clinical-stage biopharmaceutical company, today announced that it will hold its annual meeting of stockholders (the "2025 Annual Meeting") on March 23, 2026 at 10:00 a.m. Eastern Time, in virtual-only format at https://www.cstproxy.com/nrxpharma/2026, and any adjournments or postponements thereof. The Company's Board of Directors (the "Board") also set a record date of February 12, 2026

Yana Iskayeva / Getty ImagesScouted selects products independently. If you purchase something from our posts, we may earn a small commission.From facial masks that target fine lines and scarring to full-body mats designed to aid recovery, red light therapy (also known as low-level light therapy) is more accessible than ever—and emerging research suggests its benefits may extend beyond aesthetics and fitness. In fact, there is significant research that suggests that red light therapy (RLT) can be

NRX-100 (preservative-free ketamine) has been granted Fast Track Designation by FDA for treatment of suicidal ideation in patients with Depression and Bipolar Depression.Real-world evidence, consistent with FDA guidance, is supplied and generated by Osmind using its nationwide electronic medical records-derived...

Omniscient secures new AMA CPT® code for connectomic analysis, validating Quicktome’s clinical utility in brain care and advancing reimbursement.

NRX-100 (preservative-free ketamine) has been granted Fast Track Designation by FDA for treatment of suicidal ideation in patients with Depression and Bipolar Depression.Real-world evidence, consistent with FDA guidance, is supplied and generated by Osmind using its nationwide electronic medical records-derived dataset.Previously presented preliminary analysis of a 20,000 patient subset documented rapid resolution of depression and suicidality with initiation of intravenous ketamine.Analyses sug

In a new study, WashU Medicine researchers show that vagus nerve stimulation from a small, implanted device provides substantial, long-lasting improvements for some participants with the most severe treatment-resistant depression.

Researchers report a novel target for treating depression and anxiety.

BURLINGTON, Mass. and JERUSALEM, Jan. 12, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive brain stimulation technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted Premarket Approval (PMA) for Neurolief's ProlivTMRx system, a Class III device, as an adjunctive treatment for adult patients suffering from major depressive disorder (MDD) who have failed to achieve satisfactory im

(MENAFN - Send2Press Newswire) LOS ANGELES, Calif., Jan. 12, 2026 (SEND2PRESS NEWSWIRE) - The Citizens Commission on Human Rights International (CCHR), a 57-year mental health industry watchdog, is ...